287 related articles for article (PubMed ID: 22227590)
1. IL-2-targeted therapy ameliorates the severity of graft-versus-host disease: ex vivo selective depletion of host-reactive T cells and in vivo therapy.
Yarkoni S; Prigozhina TB; Slavin S; Askenasy N
Biol Blood Marrow Transplant; 2012 Apr; 18(4):523-35. PubMed ID: 22227590
[TBL] [Abstract][Full Text] [Related]
2. Targeted therapy to the IL-2R using diphtheria toxin and caspase-3 fusion proteins modulates Treg and ameliorates inflammatory colitis.
Yarkoni S; Sagiv Y; Kaminitz A; Farkas DL; Askenasy N
Eur J Immunol; 2009 Oct; 39(10):2850-64. PubMed ID: 19735074
[TBL] [Abstract][Full Text] [Related]
3. Intravenous apoptotic spleen cell infusion induces a TGF-beta-dependent regulatory T-cell expansion.
Kleinclauss F; Perruche S; Masson E; de Carvalho Bittencourt M; Biichle S; Remy-Martin JP; Ferrand C; Martin M; Bittard H; Chalopin JM; Seilles E; Tiberghien P; Saas P
Cell Death Differ; 2006 Jan; 13(1):41-52. PubMed ID: 15962005
[TBL] [Abstract][Full Text] [Related]
4. Depletion of naïve lymphocytes with fas ligand ex vivo prevents graft-versus-host disease without impairing T cell support of engraftment or graft-versus-tumor activity.
Askenasy N; Mizrahi K; Ash S; Askenasy EM; Yaniv I; Stein J
Biol Blood Marrow Transplant; 2013 Feb; 19(2):185-95. PubMed ID: 23078782
[TBL] [Abstract][Full Text] [Related]
5. Pharmacologic expansion of donor-derived, naturally occurring CD4(+)Foxp3(+) regulatory T cells reduces acute graft-versus-host disease lethality without abrogating the graft-versus-leukemia effect in murine models.
Duramad O; Laysang A; Li J; Ishii Y; Namikawa R
Biol Blood Marrow Transplant; 2011 Aug; 17(8):1154-68. PubMed ID: 21145405
[TBL] [Abstract][Full Text] [Related]
6. Recipient type-specific engineered regulatory T cells prevent graft-vs-host disease after allogeneic bone marrow transplantation in mice.
Chen C; Cao J; Zeng L; Li Y; Wang D; Xu K
Transplant Proc; 2011 Jun; 43(5):2041-8. PubMed ID: 21693322
[TBL] [Abstract][Full Text] [Related]
7. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response.
Jones SC; Murphy GF; Korngold R
Biol Blood Marrow Transplant; 2003 Apr; 9(4):243-56. PubMed ID: 12720217
[TBL] [Abstract][Full Text] [Related]
8. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation.
Edinger M; Hoffmann P; Ermann J; Drago K; Fathman CG; Strober S; Negrin RS
Nat Med; 2003 Sep; 9(9):1144-50. PubMed ID: 12925844
[TBL] [Abstract][Full Text] [Related]
9. A fusion protein composed of IL-2 and caspase-3 ameliorates the outcome of experimental inflammatory colitis.
Sagiv Y; Kaminitz A; Lorberboum-Galski H; Askenasy N; Yarkoni S
Ann N Y Acad Sci; 2009 Sep; 1173():791-7. PubMed ID: 19758230
[TBL] [Abstract][Full Text] [Related]
10. Ex vivo rapamycin generates Th1/Tc1 or Th2/Tc2 Effector T cells with enhanced in vivo function and differential sensitivity to post-transplant rapamycin therapy.
Jung U; Foley JE; Erdmann AA; Toda Y; Borenstein T; Mariotti J; Fowler DH
Biol Blood Marrow Transplant; 2006 Sep; 12(9):905-18. PubMed ID: 16920556
[TBL] [Abstract][Full Text] [Related]
11. Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution.
Gendelman M; Yassai M; Tivol E; Krueger A; Gorski J; Drobyski WR
Biol Blood Marrow Transplant; 2003 Dec; 9(12):742-52. PubMed ID: 14677113
[TBL] [Abstract][Full Text] [Related]
12. Ex vivo expanded human CD4+CD25+Foxp3+ regulatory T cells prevent lethal xenogenic graft versus host disease (GVHD).
Cao T; Soto A; Zhou W; Wang W; Eck S; Walker M; Harriman G; Li L
Cell Immunol; 2009; 258(1):65-71. PubMed ID: 19410243
[TBL] [Abstract][Full Text] [Related]
13. Tracking ex vivo-expanded CD4+CD25+ and CD8+CD25+ regulatory T cells after infusion to prevent donor lymphocyte infusion-induced lethal acute graft-versus-host disease.
Xia G; Kovochich M; Truitt RL; Johnson BD
Biol Blood Marrow Transplant; 2004 Nov; 10(11):748-60. PubMed ID: 15505606
[TBL] [Abstract][Full Text] [Related]
14. Amelioration of acute graft-versus-host disease by adoptive transfer of ex vivo expanded human cord blood CD4+CD25+ forkhead box protein 3+ regulatory T cells is associated with the polarization of Treg/Th17 balance in a mouse model.
Yang J; Fan H; Hao J; Ren Y; Chen L; Li G; Xie R; Yang Y; Qian K; Liu M
Transfusion; 2012 Jun; 52(6):1333-47. PubMed ID: 22098312
[TBL] [Abstract][Full Text] [Related]
15. Blockade of chronic graft-versus-host disease by alloantigen-induced CD4+CD25+Foxp3+ regulatory T cells in nonlymphopenic hosts.
Giorgini A; Noble A
J Leukoc Biol; 2007 Nov; 82(5):1053-61. PubMed ID: 17684039
[TBL] [Abstract][Full Text] [Related]
16. Ex vivo anti-CD3 antibody-activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease but retain their ability to facilitate alloengraftment.
Drobyski WR; Majewski D; Ozker K; Hanson G
J Immunol; 1998 Sep; 161(5):2610-9. PubMed ID: 9725263
[TBL] [Abstract][Full Text] [Related]
17. Contribution of CD4+ and CD8+ T cells to graft-versus-host disease and graft-versus-leukemia reactivity after transplantation of MHC-compatible bone marrow.
Truitt RL; Atasoylu AA
Bone Marrow Transplant; 1991 Jul; 8(1):51-8. PubMed ID: 1833016
[TBL] [Abstract][Full Text] [Related]
18. Induced regulatory T cells promote tolerance when stabilized by rapamycin and IL-2 in vivo.
Zhang P; Tey SK; Koyama M; Kuns RD; Olver SD; Lineburg KE; Lor M; Teal BE; Raffelt NC; Raju J; Leveque L; Markey KA; Varelias A; Clouston AD; Lane SW; MacDonald KP; Hill GR
J Immunol; 2013 Nov; 191(10):5291-303. PubMed ID: 24123683
[TBL] [Abstract][Full Text] [Related]
19. Radiosensitivity and responsiveness to recombinant interleukin-2 of effector cells of graft vs. host disease and mixed lymphocyte reaction in mice.
Stark J; Weiss L; Slavin S
Isr J Med Sci; 1992 Nov; 28(11):767-72. PubMed ID: 1468887
[TBL] [Abstract][Full Text] [Related]
20. FTY720 enhances the activation-induced apoptosis of donor T cells and modulates graft-versus-host disease.
Hashimoto D; Asakura S; Matsuoka K; Sakoda Y; Koyama M; Aoyama K; Tanimoto M; Teshima T
Eur J Immunol; 2007 Jan; 37(1):271-81. PubMed ID: 17154260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
